Enveric Biosciences Secures Patent for Drug Candidate

Enveric Biosciences, a biotechnology firm focused on developing innovative neuroplastogens for neuropsychiatric disorders, has secured expanded protection for its potential clinical uses of the drug candidate EB-002. The United States Patent and Trademark Office has granted Patent No. 11,945,778, which significantly broadens the company's intellectual property rights. This new patent covers methods of treating a wide array of brain neurological disorders, including sleep disorders, depression, substance-related issues, and headaches.

EB-002 is Enveric's next-generation psilocin prodrug, designed initially to address anxiety disorders. The recent patent adds to the compound's existing protections, enhancing its potential to treat a variety of neurological conditions and serve a diverse patient base. The CEO of Enveric, Joseph Tucker, Ph.D., highlighted that EB-002 now has U.S. patent protection under three issued patents. These patents cover the compositions and pharmaceutical formulations of EB-002 and closely related compounds, methods for creating these molecules, and methods for treating a broad spectrum of brain neurological disorders using EB-002 and similar compounds. Additionally, Patent Cooperation Treaty (PCT) applications are pending.

Dr. Tucker emphasized that a comprehensive patent portfolio is crucial for protecting lead drug candidates, aiding in de-risking and expediting clinical development. This approach supports Enveric’s mission to quickly bring new drugs to patients in need.

Enveric Biosciences, listed on NASDAQ under the ticker symbol ENVB, specializes in developing novel neuroplastogenic small-molecule therapeutics aimed at treating depression, anxiety, and addiction disorders. Utilizing its proprietary discovery and development platform known as Psybrary™, the company has built a strong intellectual property portfolio of new chemical entities targeting specific mental health conditions. Enveric's leading program, EB-003, offers a groundbreaking approach to treating challenging mental health disorders. It is designed to promote neuroplasticity without causing hallucinations in patients. Additionally, Enveric is advancing EB-002, a next-generation synthetic prodrug of psilocin, for the treatment of psychiatric disorders.

Enveric is headquartered in Naples, Florida, with additional offices in Cambridge, Massachusetts, and Calgary, Alberta, Canada. The company's strategic locations support its robust research and development activities in the field of neuropsychiatric therapeutics.